Fangzhou Advances AI-Enabled Healthcare Solutions at PHARMCHINA

Fangzhou Showcases AI-Driven Healthcare Ecosystem at PHARMCHINA

On May 29, 2025, Fangzhou Inc., a leader in internet healthcare solutions, made a significant impression at the 4th Annual "Internet + Pharma" Service Innovation Conference, part of the 90th PHARMCHINA exhibition in Guangzhou. This event featured the introduction of Fangzhou's AI-powered healthcare ecosystem, which aims to revolutionize medical delivery through technology. With over 300 industry experts in attendance, the conference reflected China's commitment to accelerating digitization within the healthcare sector.

The conference coincided with the unveiling of the 2025-2030 Pharmaceutical Industry Digital Transformation Implementation Plan, developed through collaborative efforts of various regulatory organizations, including the Ministry of Industry and Information Technology (MIIT) and the National Health Commission. This initiative marks a pivotal moment in China's healthcare landscape, focusing on enhancing accessibility and efficiency in healthcare delivery.

Keynote Highlights

In his keynote address, Fangzhou's founder and CEO, Dr. Xie Fangmin, emphasized the importance of their H2H (Hospital-to-Home) smart healthcare ecosystem. He stated, "Our ecosystem leverages advanced AI tools that align with the healthcare industry roadmap, ultimately enhancing healthcare accessibility across China."

Guo Zhi, Senior Vice President of Technology at Fangzhou, outlined recent advancements in their AI-driven ecosystem, particularly showcasing innovative solutions that address hallucination risks in medical large language models. By incorporating intelligent pre-consultation capabilities through an AI assistant, Fangzhou is significantly improving patient satisfaction and operational efficiency. Guo asserted that "AI is transforming healthcare from labor-intensive procedures to algorithm-driven processes," thus supporting the company’s strategy in handling the dual challenges of an aging population and increased healthcare demands.

Strategic Shift Towards AI Integration

The emphasis on AI adoption within national policies signifies a clear shift in China’s regulatory and developmental priorities. The Implementation Plan identifies AI and digital transformation as essential for industry progress, signaling a comprehensive approach to modernize healthcare. This policy momentum is prompting healthcare enterprises across the country to embrace smart technologies, reshaping their operational strategies to meet future demands.

Fangzhou's commitment to deepening AI integration illustrates its alignment with overarching national goals for healthcare advancement. The company has reported significant growth, with 49.2 million registered users and 223,000 physicians utilizing its platform as of December 31, 2024. The focus on personalized care and precision medicine positions Fangzhou as a leader in the online chronic disease management sector.

The Future of Healthcare

With a focus on collaboration among government, industry, academia, and medical sectors, the 4th "Internet + Pharma" Service Innovation Conference emphasized pathways for the pharmaceutical industry's transformation. Fangzhou's innovative solutions and strategic direction are paving the way for a more efficient, accessible, and technology-driven healthcare sector in China.

In summary, Fangzhou's role at PHARMCHINA accentuates the importance of AI in healthcare and reflects its commitment to supporting China's digital transformation. As the company continues to innovate and adapt to changing healthcare landscapes, it remains poised to lead the charge toward a smarter, more integrated approach to health management in the future.